Amicus Therapeutics Inc
NASDAQ:FOLD

Watchlist Manager
Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc
NASDAQ:FOLD
Watchlist
Price: 14.24 USD -0.07%
Market Cap: 4.4B USD

Wall Street
Price Targets

FOLD Price Targets Summary
Amicus Therapeutics Inc

Wall Street analysts forecast FOLD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FOLD is 16.26 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.

Lowest
Price Target
14.14 USD
1% Downside
Average
Price Target
16.26 USD
14% Upside
Highest
Price Target
23.1 USD
62% Upside
Amicus Therapeutics Inc Competitors:
Price Targets
NTLA
Intellia Therapeutics Inc
146% Upside
LGND
Ligand Pharmaceuticals Inc
31% Upside
AZT
Arcticzymes Technologies ASA
63% Upside
1530
3SBio Inc
56% Upside
302440
SK Bioscience Co Ltd
18% Downside
KALV
Kalvista Pharmaceuticals Inc
96% Upside
4587
PeptiDream Inc
94% Upside
LXRX
Lexicon Pharmaceuticals Inc
155% Upside

Revenue
Forecast

Revenue Estimate
Amicus Therapeutics Inc

For the last 13 years the compound annual growth rate for Amicus Therapeutics Inc's revenue is 28%. The projected CAGR for the next 4 years is 20%.

28%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Amicus Therapeutics Inc

The compound annual growth rate of Amicus Therapeutics Inc's operating income for the next 4 years is 84%.

N/A
Past Growth
84%
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

Net Income Estimate
Amicus Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-40%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FOLD's stock price target?
Price Target
16.26 USD

According to Wall Street analysts, the average 1-year price target for FOLD is 16.26 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.

What is Amicus Therapeutics Inc's Revenue forecast?
Projected CAGR
20%

For the last 13 years the compound annual growth rate for Amicus Therapeutics Inc's revenue is 28%. The projected CAGR for the next 4 years is 20%.

What is Amicus Therapeutics Inc's Operating Income forecast?
Projected CAGR
84%

The compound annual growth rate of Amicus Therapeutics Inc's operating income for the next 4 years is 84%.

Back to Top